Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Safety Issues Will Raise Regulatory Expectations, Bristol Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol expects a more critical regulatory environment for its recently submitted muraglitazar NDA. Greater scrutiny by FDA could translate into more focused labeling, CEO Dolan says.

You may also be interested in...



Bristol's Abatacept Launch Supply Limited Until FDA Clears Contract Facility

Company faces the possibility of nearly 12 months of limited supply of the rheumatoid arthritis therapy until third-party manufacturer Lonza is approved by FDA, which could occur in mid-2006. Bristol completed the abatacept rolling BLA at the end of March and has requested a priority review.

Bristol's Abatacept Launch Supply Limited Until FDA Clears Contract Facility

Company faces the possibility of nearly 12 months of limited supply of the rheumatoid arthritis therapy until third-party manufacturer Lonza is approved by FDA, which could occur in mid-2006. Bristol completed the abatacept rolling BLA at the end of March and has requested a priority review.

Pravachol OTC Deal Reached Between Bayer, Bristol

Bristol will handle the regulatory filing of the switch NDA and advisory committee presentation for pravastatin 20 mg, while Bayer Consumer Care will handle OTC sales and marketing if FDA approves the cholesterol-lowering agent for nonprescription sale.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel